Abstract
Question necessary for recommendation development: How does the immunogenicity (humoral and mucosal) of an IPV-only schedule compare to a bOPV/IPV schedule? What is the preferred IPV-only schedule?
Question necessary for recommendation development: How does the immunogenicity (humoral and mucosal) of an IPV-only schedule compare to a bOPV/IPV schedule? What is the preferred IPV-only schedule?